Chembio Diagnostics (NASDAQ:CEMI) issued its earnings results on Thursday. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.10), Fidelity Earnings reports. The company had revenue of $9.38 million for the quarter. Chembio Diagnostics had a negative return on equity of 26.91% and a negative net margin of 16.54%.
Shares of NASDAQ CEMI traded down $0.47 during trading on Friday, hitting $6.78. 727,980 shares of the company were exchanged, compared to its average volume of 126,979. The firm has a market capitalization of $103.83 million, a P/E ratio of -13.04 and a beta of 1.46. Chembio Diagnostics has a 1 year low of $6.44 and a 1 year high of $11.55. The company has a debt-to-equity ratio of 0.02, a quick ratio of 2.58 and a current ratio of 3.53.
In related news, insider Robert Passas bought 15,000 shares of the firm’s stock in a transaction on Monday, November 5th. The shares were bought at an average cost of $6.75 per share, for a total transaction of $101,250.00. Following the transaction, the insider now owns 15,000 shares of the company’s stock, valued at $101,250. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 4.65% of the stock is currently owned by insiders.
Chembio Diagnostics, Inc, together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or monitor diseases. It offers tests for HIV and Syphilis, and Zika virus. The company also develops tests for malaria, Dengue virus, chikungunya virus, Ebola, Lassa, Marburg, leptospirosis, Rickettsia typhi, Burkholderia pseudomallei, and Orientia tsutsugamushi.
Featured Article: Why do corrections happen?
Receive News & Ratings for Chembio Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chembio Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.